fa Pharmacological كاربردي Review/Systemtic review <span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:115%"><span calibri=""><b><span new="" roman="" times="">Objective:</span></b> <span new="" roman="" times="">Ovarian cancer remains highly lethal, primarily due to late-stage diagnosis and the limitations of conventional therapies, which are often associated with systemic toxicity and limited tumor specificity. Nanoparticles, owing to their nanoscale dimensions, high surface-to-volume ratio, and capacity for surface functionalization, offer improved drug delivery and precise tumor targeting. This review provides a comprehensive summary of the principal types of nanoparticles employed in ovarian cancer therapy, with an emphasis on their mechanisms of action and therapeutic efficacy.</span></span></span><br> <span style="line-height:115%"><span calibri=""><b><span new="" roman="" times="">Methods:</span></b> <span new="" roman="" times="">This narrative review synthesizes findings from experimental and preclinical studies investigating nanoparticle-based interventions in ovarian cancer. Relevant publications were identified through systematic searches of established scientific databases, including PubMed, Scopus, and Google Scholar. Studies focusing on nanoparticle design, targeting strategies, drug-loading efficiency, and therapeutic outcomes were critically evaluated and analyzed.</span></span></span><br> <span style="line-height:115%"><span calibri=""><b><span new="" roman="" times="">Results:</span></b> <span new="" roman="" times="">A diverse range of nanostructures has been investigated for the treatment of ovarian cancer. These include magnetoelectric CoFe₂O₄@BaTiO₃ nanoparticles; poly(lactic-co-glycolic acid) (PLGA)-based nanoplatforms co-delivering cisplatin and HER2-targeted antibodies; biodegradable periodic mesoporous organosilica (PMO) nanoparticles loaded with doxorubicin; polymer-based immunotargeted nanoparticles (NPs&ndash;Tx&ndash;HER); mesoporous silica nanoparticles (MSNPs); poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanoparticles encapsulating paclitaxel; PARP1-targeted small interfering RNA (siRNA) nanocarriers; folate-conjugated lipid nanoparticles; cathepsin B&ndash;responsive doxorubicin prodrug nanoparticles; and PTP@SR-717 nanocomplexes. Across in vitro and in vivo models, these nanosystems have demonstrated enhanced tumor-specific accumulation, improved intracellular drug delivery, reduced systemic toxicity, and potentiation of chemotherapeutic and immunotherapeutic efficacy.</span></span></span><br> <span style="line-height:115%"><span calibri=""><b><span new="" roman="" times="">Conclusion:</span></b> <span new="" roman="" times="">Nanoparticle-based therapies represent a significant advancement in ovarian cancer treatment, enabling precise tumor targeting and controlled drug release. This approach minimizes the systemic toxicity commonly associated with conventional chemotherapy while enhancing anticancer efficacy. When integrated with cytotoxic agents, gene-silencing molecules, or monoclonal antibodies, nanoparticle platforms facilitate the development of personalized and more effective therapeutic strategies. Ultimately, these innovations hold considerable potential to improve clinical outcomes and enhance patients&rsquo; quality of life.</span></span></span><br> <img alt="" src="./files/site1/images/copuediting.png" style="width: 586px; height: 265px;" ></span></span> 170 184 http://pbp.medilam.ac.ir/browse.php?a_code=A-10-1553-3&slc_lang=fa&sid=1 Maryam Aghdaki maryam.aghdaki@yahoo.com 10031947532846006288 10031947532846006288 No Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Sima Kamkari Sima.kamkari@gmail.com 10031947532846006289 10031947532846006289 Yes Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran